AtriCure Inc (ATRC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AtriCure Inc (ATRC) has a cash flow conversion efficiency ratio of 0.043x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($22.19 Million) by net assets ($516.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ATRC market cap for the company's overall valuation and market capitalisation.
AtriCure Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how AtriCure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AtriCure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AtriCure Inc ranked by their cash flow conversion efficiency. Explore ATRC cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cadeler As
OL:CADLR
|
0.148x |
|
Imerys SA
PA:NK
|
0.054x |
|
Lotte Shopping
KO:023530
|
0.036x |
|
Schiehallion Fund Ltd
LSE:MNTN
|
-0.005x |
|
China Railway Hi-tech Industry Corp Ltd
SHG:600528
|
0.101x |
|
Metcash Ltd
AU:MTS
|
0.157x |
|
Maanshan Iron & Steel Co Ltd
SHG:600808
|
-0.004x |
|
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
SHE:000766
|
-0.003x |
Annual Cash Flow Conversion Efficiency for AtriCure Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of AtriCure Inc from 2004 to 2025. View AtriCure Inc (ATRC) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $491.94 Million | $57.33 Million | 0.117x | +340.22% |
| 2024-12-31 | $460.97 Million | $12.20 Million | 0.026x | +175.24% |
| 2023-12-31 | $466.17 Million | $4.48 Million | 0.010x | +119.84% |
| 2022-12-31 | $456.75 Million | $-22.14 Million | -0.048x | -70.17% |
| 2021-12-31 | $483.76 Million | $-13.78 Million | -0.028x | +40.88% |
| 2020-12-31 | $412.39 Million | $-19.87 Million | -0.048x | +24.63% |
| 2019-12-31 | $247.34 Million | $-15.81 Million | -0.064x | -282.19% |
| 2018-12-31 | $249.38 Million | $-4.17 Million | -0.017x | +69.86% |
| 2017-12-31 | $161.17 Million | $-8.94 Million | -0.055x | +38.17% |
| 2016-12-31 | $168.44 Million | $-15.12 Million | -0.090x | -113.68% |
| 2015-12-31 | $186.69 Million | $-7.84 Million | -0.042x | +74.22% |
| 2014-12-31 | $132.54 Million | $-21.60 Million | -0.163x | -126.59% |
| 2013-12-31 | $72.60 Million | $-5.22 Million | -0.072x | +53.56% |
| 2012-12-31 | $12.50 Million | $-1.94 Million | -0.155x | -21.75% |
| 2011-12-31 | $15.61 Million | $-1.99 Million | -0.127x | -6267.96% |
| 2010-12-31 | $16.74 Million | $-33.43K | -0.002x | -108.13% |
| 2009-12-31 | $17.09 Million | $419.95K | 0.025x | +112.53% |
| 2008-12-31 | $29.12 Million | $-5.71 Million | -0.196x | +12.45% |
| 2007-12-31 | $36.24 Million | $-8.12 Million | -0.224x | +44.85% |
| 2006-12-31 | $30.69 Million | $-12.47 Million | -0.406x | -130.28% |
| 2005-12-31 | $43.18 Million | $-7.62 Million | -0.176x | -226.84% |
| 2004-12-31 | $-27.33 Million | $-3.80 Million | 0.139x | -- |
About AtriCure Inc
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; m… Read more